Effect of hyperhomocysteinemia on protein C activation and activity
Open Access
- 15 September 2002
- journal article
- Published by American Society of Hematology in Blood
- Vol. 100 (6) , 2108-2112
- https://doi.org/10.1182/blood-2002-03-0727
Abstract
Hyperhomocysteinemia has been proposed to inhibit the protein C anticoagulant system through 2 mechanisms: decreased generation of activated protein C (APC) by thrombin, and resistance to APC caused by decreased inactivation of factor Va (FVa). We tested the hypotheses that generation of APC by thrombin is impaired in hyperhomocysteinemia in monkeys and that hyperhomocysteinemia produces resistance to APC in monkeys, mice, and humans. In a randomized crossover study, cynomolgus monkeys were fed either a control diet or a hyperhomocysteinemic diet for 4 weeks. Plasma total homocysteine (tHcy) was approximately 2-fold higher when monkeys were on the hyperhomocysteinemic diet than when they were on the control diet (9.8 ± 2.0 μM versus 5.6 ± 1.0 μM; P < .05). After infusion of human thrombin (25 μg/kg of body weight), the peak level of plasma APC was 136 ± 16 U/mL in monkeys fed the control diet and 127 ± 13 U/mL in monkeys fed the hyperhomocysteinemic diet (P > .05). The activated partial thromboplastin time was prolonged to a similar extent by infusion of thrombin in monkeys fed the control diet and in those fed the hyperhomocysteinemic diet. The sensitivity of plasma FV to human APC was identical in monkeys on control diet and those on hyperhomocysteinemic diet. We also did not detect resistance of plasma FV to APC in hyperhomocysteinemic mice deficient in cystathionine β-synthase (plasma tHcy, 93 ± 16 μM) or in human volunteers with acute hyperhomocysteinemia (plasma tHcy, 45 ± 6 μM). Our findings indicate that activation of protein C by thrombin and inactivation of plasma FVa by APC are not impaired during moderate hyperhomocysteinemia in vivo.Keywords
This publication has 29 references indexed in Scilit:
- Relative Roles of Albumin and Ceruloplasmin in the Formation of Homocystine, Homocysteine-Cysteine-mixed Disulfide, and Cystine in CirculationJournal of Biological Chemistry, 2001
- Homocysteine Inhibits Inactivation of Factor Va by Activated Protein CJournal of Biological Chemistry, 2001
- Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemiaJournal of Clinical Investigation, 2000
- Homocysteine and Its Disulfide DerivativesArteriosclerosis, Thrombosis, and Vascular Biology, 2000
- Impaired Anticoagulant Response to Infusion of Thrombin in Atherosclerotic Monkeys Associated With Acquired Defects in the Protein C SystemArteriosclerosis, Thrombosis, and Vascular Biology, 1999
- Activated Protein C Resistance and Thrombosis: Molecular Mechanisms of Hypercoagulable State Due to FVR506Q MutationSeminars in Thrombosis and Hemostasis, 1999
- Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia.Journal of Clinical Investigation, 1996
- Conversion of thrombin into an anticoagulant by protein engineeringNature, 1995
- Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine.Journal of Clinical Investigation, 1991
- Homocyst(e)inemia in daily practiceCoronary Artery Disease, 1990